AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06650124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil + Prednisolone Participants will receive mycophenolate mofetil in combination.
Description: Participants in this arm will receive mycophenolate mofetil (MMF) starting at 1,000 mg/day for the first two weeks, increasing to 2,000 mg/day thereafter. This will be combined with prednisolone, beginning at 40-60 mg/day, with a tapering dose to 5-10 mg/day after 4-8 weeks, depending on the patient's response. MMF works by inhibiting inosine monophosphate dehydrogenase, which decreases lymphocyte proliferation, thereby reducing immune-mediated liver damage in autoimmune hepatitis. Prednisolone, a corticosteroid, is included to control inflammation during the induction phase of treatment. This intervention lasts for 24 weeks, with monitoring for biochemical remission (normalization of liver enzymes and IgG levels) and adverse events to assess the treatment's safety and efficacy.
Study NCT06650124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine + Prednisolone
Description: In this arm, participants will receive azathioprine (AZA) starting at 50 mg/day for the first two weeks, followed by an increase to 100 mg/day. This dose will be combined with prednisolone, starting at 40-60 mg/day, with the dosage tapering to 5-10 mg/day after 4-8 weeks, depending on patient response. Azathioprine works as an immunosuppressive agent by inhibiting DNA synthesis in rapidly dividing immune cells, thereby reducing liver inflammation in autoimmune hepatitis. Prednisolone, a corticosteroid, is included to control inflammation during the initial treatment phase. The intervention lasts for 24 weeks with regular monitoring for biochemical remission, defined as normalization of liver enzymes (AST, ALT) and IgG levels, as well as the occurrence of adverse events to assess safety and tolerability.
Study NCT04478240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PeerLearning.net
Description: PeerLearning.net is a software package that supports teachers in designing and delivering peer learning lessons, either in-person or remotely while students are learning at home.~Peer learning is an instructional technique that puts students in groups under conditions of positive interdependence, where they are incentivized to work together and promote the success of one another. Peer Learning lessons also ensure individual accountability and explicitly observe for and reward specific group social skills (e.g., encouraging participation, checking for understanding). Peer Learning also includes group processing after the lesson is completed so that the students in the groups have an opportunity to discuss what they did well and what could use improvement; they also have the opportunity to provide positive reinforcement to one another for contributing to the success of the group.
Study NCT04663061 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes education
Description: Participants will receive standard of care diabetes education
Study NCT04663061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Description: Participants will use CGM devices to track blood glucose levels in near real time
Study NCT04804540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion
Study NCT05183815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: slow stroke massage and murrotal quran
Description: murrotal quran and slow stroke massage
Study NCT06530225 — intervention group
Intervention type: OTHER
Intervention: Education and Mentoring for Prescribing Pharmacists
Description: Pharmacists enrolled in the PrEP prescribing cohort will receive implicit bias, health disparity and health equity training for HIV prevention. In addition, the pharmacists will receive mentorship and receive an implementation toolkit on best practices for PrEP prescribing.
Study NCT05578248 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Non-invasive imaging technology that produces three-dimensional detailed anatomical images
Study NCT05578248 — intervention group
Intervention type: PROCEDURE
Intervention: ACL reconstruction
Description: Surgical procedure to repair damaged or severed anterior cruciate ligament in the knee
Study NCT06462144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMPT-514 CART Cell Injection
Description: CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
Study NCT05578079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Intervention-1 group will listen to the classical music that the Arts of Fugue by Bach.
Study NCT05578079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Intervention-2 group will listen to lullaby.
Study NCT06331026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with new preparation (T)
Description: A single subcutaneous injection of PEG-rhGH with new preparation
Study NCT04499131 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Cycle (no intervention)
Description: Control group of 19 subjects in the context of a natural cycle with only endogenous progesterone present
Study NCT05515796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terelizumab (aka Tislelizumab)
Description: q3w Terelizumab (aka Tislelizumab) 200mg on day 1 of each cycle
Study NCT05515796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CapeOx
Description: Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days
Study NCT06284304 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: De-escalated radiotherapy
Description: 5 fraction de-escalated dose SBRT protocol
Study NCT05515796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: q3w Trastuzumab (6 mg/kg following an initial loading dose of 8 mg/kg) on day 1 of each cycle
Study NCT05515796 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 25 Gy/5 fractions
Study NCT06331026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with present preparation (R)
Description: A single subcutaneous injection of PEG-rhGH with present preparation
Study NCT04784065 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand orthosis
Description: An orthosis applied to a hand affected by osteoarthritis with the expectation that it will improve symptoms and possibly structural progression.
Study NCT04784065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand orthosis
Description: An orthosis applied to a hand affected by osteoarthritis with the expectation that it will improve symptoms and possibly structural progression.
Study NCT06176144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Desflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled desflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), and sufentanil (administered by intermittent injection).Towards the end of surgery, desflurane inhalational concentration will be decreased and sufentanil will be administered when necessary. Desflurane inhalation will be stopped at the end of surgery.
Study NCT06176144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection).Towards the end of surgery, sevoflurane inhalational concentration will be decreased and sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery.
Study NCT05355051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine
Description: Given by Vein (IV)
Study NCT05355051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by Vein (IV)
Study NCT05811832 — intervention group
Intervention type: OTHER
Intervention: Evaluation
Description: Modified Medical research Council , Saint George Respiratory Two Minute Walk Test,Frail fragility scale ,Prisma-7 Vulnerability scale,Pase,Berg balance scale,manual muscle test,quadriceps muscle strength, hand dynamometer,Fatigue Severity Scale
Study NCT05648500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenerimod
Description: Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.
Study NCT05648500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
Study NCT06275971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6
Description: Glycemic control was monitored using CGM data for seven days following cardiac surgery
Study NCT05484609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OUD scenario
Description: The patient actor will make unannounced phone calls to family physicians asking for a new patient appointment. The patient actor will play the role of a patient with opioid use disorder undergoing methadone treatment with an addiction physician.
Study NCT05484609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes scenario
Description: The patient actor will make unannounced phone calls to family physicians asking for a new patient appointment. The patient actor will play the role of patient with diabetes in treatment with an endocrinologist.
Study NCT03934996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Runners with educational training
Description: Intervention will consist of an educational talk to know the anatomy and function of the Pelvic Floor Muscles and 20 minutes of both strength and endurance exercises with biofeedback. An exercise protocol will be carried out. The participants will be instruct to contract and maintain maximum force for a mean period of 6 seconds (endurance training) and rest for twice the length of the endurance training time, followed by three fast contractions in a row as strength training. It will be done twice a week, during 12 weeks.~Pelvic floor assesment: Perineometry, manual palpation, electromyography Trunk and lower limbs electromyography and kinematics
Study NCT05735418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GI Biome #7
Description: It comprises probiotics (Lactobacillus fermentum, Lactobacillus acidophilus, Lactobacillus plantarum, and Bifidobacterium animalis ssp. lactis) and prebiotics (vitamin B2., Korean red ginseng, and etc.). The administration dosage of probiotics is 5×10\^8 CFU/day.
Study NCT05735418 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of daily administration of the placebo pills made up of 100% maltodextrin for four weeks.
Study NCT06548477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human albumin
Description: Patients in intervention arm will also receive intermittent boluses of 20 percent human albumin (in addition to standard fluid therapy) that will be administered with dosage regimen of 1.25gm/kg of body weight per 24 hours. The maximum total calculated dose/volume of albumin for the patient will be infused @ 34 ml/hour (over 3 hours) and will be divided in 3 boluses, spaced at 8 hours intervals. During intervention period, duration of treatment (7-day study period) will cover the peak period of cerebral vasospasm from day 4th until 10th day. Albumin administration will be tailored according to the targeted values set for euvolemic fluid balance in each patient. Before randomization (within 72 hours post-ictus) and after day-10 (from day 11th-14th, patient will only receive standard fluid therapy.
Study NCT04901546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient's own saliva
Description: Infants with esophageal atresia will be given their own saliva
Study NCT06644794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone-modified natural cycle preparation for frozen embryo transfer
Description: A novel endometrial preparation protocol that optimizes the natural cycle, whereby as long as the thickness of the endometrium is suitable for embryo transfer, vaginal progesterone can be used to transform the endometrium before ovulation and subsequently FET.
Study NCT06644794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormone replacement therapy cycle preparation for frozen embryo transfer
Description: A traditional endometrial preparation protocol is used for FET, which involves using fixed or flexible exogenous estradiol for artificial cycles. This protocol typically involves starting exogenous estradiol on day 3 or 4 of the cycle, continuing for 7-10 days, and then discontinuing. Upon determining that the endometrial thickness meets the standard, progesterone conversion of the endometrium can be performed.
Study NCT05748080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eating apples
Description: the eating of 2 apples a day for a period of 6 weeks
Study NCT06639243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QYM Technique
Description: The intervention in this study involves the application of the Quick Yielding Modified (QYM) technique for the treatment of complex aortic arch diseases. This procedure consists of two main components:~1. Thoracic Endovascular Aortic Repair (TEVAR): This minimally invasive procedure utilizes a covered stent graft to exclude the diseased segment of the thoracic aorta, providing immediate protection against rupture and controlling blood flow.~2. In Situ Fenestration and Revascularization of Supra-Aortic Branches: Following TEVAR, the QYM technique includes creating fenestrations in the stent graft to allow for the revascularization of the supra-aortic branches (such as the brachiocephalic, left common carotid, and left subclavian arteries). This is achieved through direct puncture and reconstruction of the branch vessels, ensuring adequate blood flow to these critical arteries while preserving their function.~The combination of these techniques aims to achieve effective treatment out
Study NCT06641895 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BBM-D101
Description: BBM-D101 is a recombinant adeno-associated virus vector-based gene therapy for DMD treatment. It is a suspension for single intravenous (IV) infusion.
Study NCT06642467 — intervention group
Intervention type: DEVICE
Intervention: BGEM
Description: BGEM is an ai driven model to predict blood glucose using ppg sensor
Study NCT06641544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inetetamab
Description: Group A received Inetetamab+Pertuzumab+TPC, while Group B received Inetetamab+Pyrotinib+TPC.
Study NCT06641544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inetetamab
Description: Group A received Inetetamab+Pertuzumab+TPC, while Group B received Inetetamab+Pyrotinib+TPC.
Study NCT06640777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEAF-4L6715
Description: LEAF-4L6715: Administration at a dose of 200mg , for up to 10 days every 12 hours for the first 2 days, followed by once-a-day dosing for the next 8 days (days 3 through 10).
Study NCT06640777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Supportive care, as considered necessary by the treating physician/Principal Investigator (PI), including mechanical ventilation, in line with therapeutic guidelines for ARDS and Multiorgan Failure
Study NCT06640777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Supportive care, as considered necessary by the treating physician/Principal Investigator (PI), including mechanical ventilation, in line with therapeutic guidelines for ARDS and Multiorgan Failure
Study NCT06636695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellular Matrix
Description: Group 1 (Cellular Matrix): Patients randomized to this group will be treated with two intra-articular injections of Cellular Matrix at D0 and M1.
Study NCT06636695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthovisc
Description: Group 2 (HA): Patients randomized to this group will be treated with two intra-articular injections of HA alone provided by ORTHOVISC at D0 and M1
Study NCT06639022 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus posterior superior intercostal plane block
Description: Serratus posterior superior intercostal plane block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
Study NCT06639022 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Erector spinae plane block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
Study NCT06639022 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group without peripheral nerve block
Description: In the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.
Study NCT06640218 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sealer activation with Eddy sonic and AF max
Description: activation of sealer after cleaning and shaping, before the obturation
Study NCT06640218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: without AF max or Eddy sonic sealer activation
Description: sealer without activation
Study NCT06640309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide Tablet
Description: Nicotinamide is anti-inflammatory and antioxidant.
Study NCT06640309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional synthetic antirheumatic drugs
Description: methotrexate- leflunomide- sulfasalazine- hydroxychloroquine
Study NCT06640309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional synthetic antirheumatic drugs
Description: methotrexate- leflunomide- sulfasalazine- hydroxychloroquine
Study NCT06638515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking apnea at Low Lung Volume
Description: Walking apnea at low Lung Volume Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the experimental group will perform intermittent apneas at high lung volume with a density of 5 seconds, followed by a normal breath of 5 seconds until completing the 6 minutes)
Study NCT06638515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking at normal breathing
Description: Participants walk at 6 km/h (10% slope) on treadmill for 6 minutes. Participants in the control group will remain breathing normally for these 6 minutes.
Study NCT06642883 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prolife
Description: randomized in a 1:1 ratio to treatment :1 vial/day for 60 days.
Study NCT06642883 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 1 vial/day for 60 days.
Study NCT06642987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan Test 20mg
Description: 1 tablets orally once a day
Study NCT06642987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan Reference 20mg
Description: 1 tablets orally once a day
Study NCT06644508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strict adherence to European guidelines
Description: The goal is to maintain a neutral fluid balance throughout the course of intubation if clinical practice allows. Therefore:~* From the start of mechanical ventilation, the maximum maintenance fluids is 65% of the maintenance fluids proposed by the Holliday \& Segar formula. Fluid resuscitation in the first hours after intubation is at the discretion of the attending physician.~* Any other interventions to maintain a neutral fluid balance (e.g., starting diuretics, reducing fluid boluses, decreasing creep fluids, or using more concentrated enteral feeding) are at the discretion of the attending physician.~* Throughout the intervention, the attending physician decides if clinical practice allows for a decrease in fluid balance, and international feeding goals must always be met.
Study NCT06643780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: 60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly
Study NCT06643780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zolendronic Acid
Description: 5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months
Study NCT06645301 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group A
Description: BGT007 3.0×10\^8cells,Intravenous infusion，3 subject is planned to be enrolled
Study NCT06645301 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B
Description: BGT007 6.0×10\^8cells,Intravenous infusion，6 subject is planned to be enrolled